Australian Clinical Labs Balance Sheet Health
Financial Health criteria checks 4/6
Australian Clinical Labs has a total shareholder equity of A$177.8M and total debt of A$55.1M, which brings its debt-to-equity ratio to 31%. Its total assets and total liabilities are A$593.1M and A$415.3M respectively. Australian Clinical Labs's EBIT is A$62.6M making its interest coverage ratio 3.8. It has cash and short-term investments of A$26.8M.
Key information
31.0%
Debt to equity ratio
AU$55.06m
Debt
| Interest coverage ratio | 3.8x |
| Cash | AU$26.85m |
| Equity | AU$177.77m |
| Total liabilities | AU$415.30m |
| Total assets | AU$593.06m |
Recent financial health updates
Recent updates
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Financial Position Analysis
Short Term Liabilities: ACL's short term assets (A$133.6M) do not cover its short term liabilities (A$207.7M).
Long Term Liabilities: ACL's short term assets (A$133.6M) do not cover its long term liabilities (A$207.6M).
Debt to Equity History and Analysis
Debt Level: ACL's net debt to equity ratio (15.9%) is considered satisfactory.
Reducing Debt: ACL's debt to equity ratio has reduced from 204.2% to 31% over the past 5 years.
Debt Coverage: ACL's debt is well covered by operating cash flow (289.8%).
Interest Coverage: ACL's interest payments on its debt are well covered by EBIT (3.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Australian Clinical Labs Limited is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Lyanne Harrison | BofA Global Research |
| Mathieu Chevrier | Citigroup Inc |